The rate of radiographic progression-free survival at 12 months was 65 % among patients treated with enzalutamide , as compared with 14 % among patients receiving placebo ( 81 % risk reduction ; hazard ratio in the enzalutamide group , 0.19 ; 95 % confidence interval [ CI ] , 0.15 to 0.23 ; P < 0.001 ) .